Trauma Prevalence and Its Association With Health-Related Quality of Life in Pregnant Persons with Opioid Use Disorder.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
06 Aug 2024
06 Aug 2024
Historique:
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
6
8
2024
Statut:
aheadofprint
Résumé
Trauma screening is recommended for pregnant persons with opioid use disorder (OUD), but there is limited literature on screening results from buprenorphine treatment. This study's objectives were to 1) describe the types, and severity, of traumatic events reported and 2) evaluate the associations between trauma and health-related quality of life (HRQoL). Baseline data from an ongoing trial were analyzed. Participants were 155 pregnant persons with OUD receiving, or enrolling in, buprenorphine treatment at one of 13 sites. The experience, and relative severity, of 14 high magnitude stressors were assessed with the trauma history screen. The Patient-Reported Outcomes Measurement Information System-29+2 was used to assess 8 HRQoL domains. Traumatic stressors were reported by 91% of the sample (n = 155), with 54.8% reporting a lifetime persisting posttraumatic distress (PPD) event and 29.7% reporting a childhood PPD event. The most prevalent lifetime PPD event was sudden death of a close family/friend (25.8%); physical abuse was the most prevalent childhood PPD event (10.3%). Participants with lifetime PPD, relative to no PPD, reported significantly greater pain interference (P = 0.02). Participants with childhood PPD, relative to no PPD, had significantly worse HRQoL overall (P = 0.01), and worse pain intensity (P = 0.002), anxiety (P = 0.003), depression (P = 0.007), fatigue (P = 0.002), and pain interference (P < 0.001). A majority of pregnant persons enrolled/enrolling in buprenorphine treatment reported persisting posttraumatic distress with sudden death of close family/friend being the most prevalent originating event; clinicians should consider the impact that the opioid-overdose epidemic may be having in increasing trauma exposure in patients with OUD.
Identifiants
pubmed: 39105509
doi: 10.1097/ADM.0000000000001366
pii: 01271255-990000000-00354
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 American Society of Addiction Medicine.
Déclaration de conflit d'intérêts
Conflicts of interest: AD reports royalties for academic books from OUP, Springer, PESI Publishing and from Oakstone CME. AJD reports receiving an honorarium for an online chapter on alcohol management in the perioperative period from the UpToDate online reference and serving pro bono on 3 non-for-profit Board of Directors of national/international organizations, with none of the efforts being related to the contents of this manuscript. EEK reports being an investigator on grants to Magee-Womens Research Institute from the National Institutes of Health, Gilead, and Merck outside of the submitted work. MRL reports being a research consultant for Berkshire Biomedical, Braeburn, Journey Colab, and Titan Pharmaceuticals in the last 3 years. The other authors declare no conflicts of interest.
Références
Patrick SW, Schiff DM; Committee on Substance Use and Prevention. A public health response to opioid use in pregnancy. Pediatrics. 2017;139(3):e20164070. doi:10.1542/peds.2016-4070.
doi: 10.1542/peds.2016-4070
Bruzelius E, Martins SS. US trends in drug overdose mortality among pregnant and postpartum persons, 2017–2020. JAMA. 2022;328(21):2159–2161.
Metz V, Köchl B, Fischer G. Should pregnant women with substance use disorders be managed differently? Neuropsychiatry. 2012;2(1):29–41.
Guyon-Harris KL, Jacobs J, Lavin K, et al. Perinatal substance use and the underpinnings of addiction and attachment: Implications for parenting interventions. Pract Innov. 2023;8:75–88.
Engstrom M, El-Bassel N, Gilbert L. Childhood sexual abuse characteristics, intimate partner violence exposure, and psychological distress among women in methadone treatment. J Subst Abuse Treat. 2012;43(3):366–376.
Velez ML, Montoya ID, Jansson LM, et al. Exposure to violence among substance-dependent pregnant women and their children. J Subst Abuse Treat. 2006;30(1):31–38.
Towers CV, Katz E, Liske E, et al. Psychosocial background history of pregnant women with opioid use disorder: A prospective cohort study. Am J Perinatol. 2020;37(09):924–928.
Substance Abuse, Mental Health Services Administration, Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and their Infants, Department of Health and Human Services, Rockville, MD, 2018.
Reddy UM, Davis JM, Ren Z, Greene MF. Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. Obstetrics & Gynecology. 2017;130(1):10–28.
Krans EE, Campopiano M, Cleveland LM, et al. National partnership for maternal safety: Consensus bundle on obstetric care for women with opioid use disorder. Obstet Gynecol. 2019;134(2):365–375.
Hughes K, Bellis MA, Hardcastle KA, et al. The effect of multiple adverse childhood experiences on health: A systematic review and meta-analysis. Lancet Public Health. 2017;2(8):e356–e366.
Gannon M, Short V, LaNoue M, et al. Prevalence of adverse childhood experiences of parenting women in drug treatment for opioid use disorder. Community Ment Health J. 2021;57:872–879.
El-Bassel N, Gilbert L, Schilling R, et al. Drug abuse and partner violence among women in methadone treatment. J Fam Violence. 2000;15:209–228.
Cleveland LM, McGlothen-Bell K, Scott LA, et al. A life-course theory exploration of opioid-related maternal mortality in the United States. Addiction. 2020;115(11):2079–2088.
Winhusen T, Lofwall M, Jones HE, et al. Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. Contemp Clin Trials. 2020;93:106014.
Carlson EB, Smith SR, Palmieri PA, et al. Development and validation of a brief self-report measure of trauma exposure: The trauma history screen. Psychol Assess. 2011;23(2):463–477.
Hanmer J, Dewitt B, Yu L, et al. Cross-sectional validation of the PROMIS-Preference scoring system. PloS One. 2018;13(7):e0201093.
Rencz F, Brodszky V, Janssen MF. A direct comparison of the measurement properties of EQ-5D-5L, PROMIS-29+ 2 and PROMIS global health instruments and EQ-5D-5L and PROPr utilities in a general population sample. Value Health. 2023;26:1045–1056.
Dewitt B, Jalal H, Hanmer J. Computing PROPr utility scores for PROMIS® profile instruments. Value Health. 2020;23(3):370–378.
Russo DA, Stochl J, Painter M, et al. Trauma history characteristics associated with mental states at clinical high risk for psychosis. Psychiatry Res. 2014;220(1–2):237–244.
Schneider KE, Tomko C, Nestadt DF, et al. Conceptualizing overdose trauma: The relationships between experiencing and witnessing overdoses with PTSD symptoms among street-recruited female sex workers in Baltimore, Maryland. Int J Drug Policy. 2021;92:102859.
Macmadu A, Frueh L, Collins AB, et al. Drug use behaviors, trauma, and emotional affect following the overdose of a social network member: A qualitative investigation. Int J Drug Policy. 2022;107:103792.
Kenny KS, Kolla G, Firestone M, et al. Frequency of fatal and non-fatal overdoses and response to grief and loss among people who inject drugs: An unexplored dimension of the opioid overdose crisis. Drug Alcohol Depend. 2022;237:109539.
Wang QQ, Kaelber DC, Xu R, et al. COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30–39.
Huhn AS, Dunn KE. Challenges for women entering treatment for opioid use disorder. Curr Psychiatry Rep. 2020;22:76.
Substance Abuse and Mental Health Services Administration. Trauma-Informed Care in Behavioral Health Services. Treatment Improvement Protocol (TIP) Series 57. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014.
Santo T Jr., Campbell G, Gisev N, et al. Prevalence of childhood maltreatment among people with opioid use disorder: A systematic review and meta-analysis. Drug Alcohol Depend. 2021;219:108459.
Burke NN, Finn DP, McGuire BE, et al. Psychological stress in early life as a predisposing factor for the development of chronic pain: Clinical and preclinical evidence and neurobiological mechanisms. J Neurosci Res. 2017;95(6):1257–1270.
Williams JR, Cole V, Girdler S, et al. Exploring stress, cognitive, and affective mechanisms of the relationship between interpersonal trauma and opioid misuse. PloS One. 2020;15(5):e0233185.
Schaffer J, Fogelman N, Seo D, et al. Chronic pain, chronic stress and substance use: Overlapping mechanisms and implications. Front Pain Res. 2023;4:1145934.
Manuel J, Rudolph L, Beissner F, et al. Traumatic events, posttraumatic stress disorder, and central sensitization in chronic pain patients of a German university outpatient pain clinic. Psychosom Med. 2023;85(4):351–357.
Dunn EC, Nishimi K, Gomez SH, et al. Developmental timing of trauma exposure and emotion dysregulation in adulthood: Are there sensitive periods when trauma is most harmful? J Affect Disord. 2018;227:869–877.
Weathers FW, Blake DD, Schnurr PP, et al. The Life Events Checklist for DSM-5 (LEC-5) – Standard. [Measurement instrument]. 2013; https://www.ptsd.va.gov/.